Summary Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-aminolaevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients. We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen 4 h after sensitisation at the highest doses used (200 mg kg-' i.v., 400 mg kg-' oral), and slightly earlier with lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal selectivity was achieved in each organ with each route of administration but an oral dose in excess of 40 mg kg-was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with inoperable rectal adenocarcinomas were given 30 mg kg- ' and one patient with sigmoid colon carcinoma was given 60 mg kg-' ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent 24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after administration of 30 mg kg-' ALA. There was greater PpIX accumulation in tumour than adjacent normal mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving 60 mg kg-' ALA.
Photodynamic therapy (PDT) is a promising new cancer treatment modality. Very few tumours show intrinsic resistance to PDT (Dougherty, 1990) and unlike ionising radiation and chemotherapy, PDT is devoid of general or cumulative toxicity. The basis of this therapy involves the in situ photoactivation of an otherwise non toxic drug, a photosensitiser, which has accumulated in tumour and normal tissues following parenteral administration. The resultant photochemical reaction gives rise to a highly active singlet oxygen species capable of causing cell death (Weishaupt et al., 1976 ). This effect is non selective and normal cells are just as susceptible to damage as tumour cells. However, the very short half life of this species ensures that cytotoxicity is localised only to the site of its generation which in turn partly correlates to the distribution of the photosensitiser. The most widely studied photosensitiser is Photofrin which until recently, was the only photosensitiser approved for clinical use. Photofrin, though a potent photosensitiser, causes prolonged cutaneous photosensitivity (Razum et al., 1987) and offers limited tumour selectivity (Agrez et al., 1983; Gomer & Dougherty, 1979) . We have recently reported on the photosensitisation kinetics produced by systemic administration of another agent, 5-aminolaevulinic acid (ALA) Loh et al., 1992 (Loh et al., 1992) . The photosensitisation produced is short lived lasting less than 24 h and consequently prolonged skin photosensitivity is not a problem (Divaris et al., 1990; Bedwell et al., 1992; Loh et al., 1992) . We have also demonstrated photodynamic effects on a rat colon tumour after intravenous ALA . Preliminary clinical studies have shown that ALA is taken up well by skin tumours when applied topically although the depth of penetration appears to correlate with the duration of incubation (Szeimies et al., 1992) .
ALA is supplied as a hydrochloride salt and is acidic in solution. Intravenous administration in animals of unbuffered solution is not only associated with pain (Loh, unpublished observation) but also causes bradycardia and hypotension whereas buffered ALA solution does not cause these effects (Edwards et al., 1984) . However, ALA solution buffered to a pH of 7.4 is chemically unstable (Bedwell, unpublished observation) and should be used immediately after it is made up. This makes preparation inconvenient and liable to inconsistency. Oral administration is simple, does not require full buffering and can be undertaken by patients themselves prior to therapy without supervision. As ALA is analogous to amino acids, rapid absorption can be expected following ingestion. However, little is known with regard to the photosensitisation kinetics after oral administration apart from reports of mild cutaneous photosensitivity in human volunteers after oral ingestion (Berlin et al., 1956 ). For oral delivery of ALA to be useful clinically, it should be reliably absorbed following ingestion and undergo minimal presystemic metabolism. It has recently been shown that a high serum ALA level can be achieved in human volunteer by continuous enteral infusion of ALA solution (Mustajoki et al., 1992 For the study of PpIX induced porphyrin kinetics following enteral and parenteral administration, animals were divided into two groups. Animals in the parenteral group were given 200 mg kg-' ALA intravenously into the tail vein after intramuscular anaesthesia (fentanyl and fluanisone). In the comparative enteral group, each animal received 400 mg kg-' of ALA dissolved in 1 ml of phosphate buffered saline (pH = 2.8) and administered by gastric gavage. A long bulb tip needle was introduced orally down the oesophagus into the stomach, the ALA solution injected into the stomach and the needle withdrawn. As rats are incapable of vomiting or regurgitation, all animals ingested the full delivered dose. Because of likely first-pass metabolism, a higher dose was employed for oral administration. Animals were then killed 1, 2, 4, 6, 8 and 24 h after administration for study. A disc of glandular stomach, a short segment of proximal colon and the entire bladder were excised, washed free of luminal content and immediately frozen in a bath of isopentane cooled in liquid nitrogen. Frozen specimens were mounted on OCT Biopsy specimens were taken during fibreoptic endoscopy before ingestion as well as at 2, 4, 5, 6, 7 and 8 h after ingestion from the tumour and adjacent normal rectal mucosa and prepared as above for microscopic fluorimetry. No speciment was obtained at 8 h in the third patient (MS). Microscopic fluorescence photometry of the frozen tissue sections was carried out on an inverted phase contrast microscope on which was mounted a sensitive slow scan charge coupled device (CCD) camera. The set up of this equipment has been described in detail in previous papers (Chan et al., 675 700 Wavelength (nm) Figure 1 Emission spectrum from a piece of stomach excised 4 h after intravenous administration of 200 mg kg-' ALA (peak emission wavelength = 635 nm). Excitation wavelength used was 400 nm.
1989, Bedwell et al., 1992) . Briefly, PpIX fluorescence was excited by means of an 8 mW helium neon laser (632.8 nm) which was chosen because of its spectral purity, low cost and more importantly, the relatively low tissue autofluorescence produced using this wavelength in contrast to shorter wavelength excitation. Fluorescence detection ranged from 660-710 nm. All photometry was carried out under the same magnification (10 x objective, N.A. 0.3). The fluorescence signal was processed by a personal computer into a falsely colour coded or grey scale fluorescence image of the section.
The software also enabled quantitative measurement of fluorescence levels over selected areas of interest on the displayed fluorescence image. Representative areas of mucosa, submucosa and muscularis propria were selected for fluorescence measurements which were then corrected for autofluorescence levels of each respective tissue layer as measured on specimens from control unsensitised animals. These corrected fluorescence measurements had been shown to correlate well with the total quantity of chemically extracted PpIX from tissue specimens of animals given ALA (Loh et al., in press) . Following fluorescence microscopy, the specimens were fixed in formalin and stained with haematoxylin and eosin for comparative light microscopy. The fluorescence image and its comparative light micrograph were photographed for documentation.
Results
The fluorescence emission spectrum of a piece of stomach (whole tissue) after intravenous ALA ( in Figure 1 is in good agreement with porphyrin fluorescence emission spectra from normal colon strips taken from animals injected with 200mg kg' of ALA . HPLC analysis of extracted porphyrin content (Loh et al., in press ) has recently demonstrated that after intravenous administration of 200 mg kg-' ALA to rats, more than 95%
of the porphyrin present is protoporphyrin IX in normal colon, stomach and tumour and it is reasonable to assume the same applies to oral administration. On increasing the ALA dose from 200mg kg-' to 1.6 g kg-', no change in spectral profile was observed which suggests that porphyrin aggregation which can produce a red-shift (approximately 10 nm) in the emission spectrum (Reddi & Jori, 1988) may not occur to a significant extent. Time-resolved measurements however might provide more definitive conclusions and would also help to quantify the influence of fluorescence quenching. Figure 5a and b (bladder). Highest fluorescence levels were seen in the mucosae of all three organs studied. Following oral administration, mucosal fluorescence levels rose to a peak 4 h after administration in all three organs and declined rapidly thereafter reaching background levels by 24 h (Figures 3a, 4a a 200 Hours after admin ion and 5a). With intravenous administration, peak fluorescence was achieved at 3 h after injection in gastric and vesical mucosa and 4 h in the colon. Although comparable levels of fluorescence build up occurred in the smooth muscle layers of all three organs, the gastric mucosa exhibited the highest peak fluorescence level followed by the colonic and then vesical mucosa with both routes of administration. Consequently, different levels of mucosa to muscle differential as represented by the fluorescence ratios between mucosa and muscularis ( Figure 6) ex vivo tissue specimens and HPLC analysis of chemically extracted porphyrins from animal tissue following ALA administration (Loh et al., in press ) indicate that PpIX is the predominant porphyrin produced after ALA administration.
We have recently shown satisfactory correlation of ALA induced tissue fluorescence measurements using this set up with extracted PpIX levels (Loh et al., in press ) as well as with subsequent biological effects upon light exposure in earlier studies on normal rat colon and stomach Loh et al., 1992) and moreover, the combination of microscopy and fluorimetry enables us to quantitatively map out the porphyrin fluorescence at a microscopic level, and consequently, the photodynamic effect can be predicted down to a microscopic level. Following intravenous or oral administration, a rapid build up of PpIX fluorescence occurred over the first few hours followed by an almost equally rapid decline. By 24 h, fluorescence had returned to background level. Our previous results showed that peak levels of fluorescence were achieved earlier with lower doses of ALA after intravenous administration (Loh et al., 1992 ) and the present results show the same is true for oral administration. At the highest doses used (200 mg kg-' intravenously and 400 mg kg-' orally), the peak occurred 4 h after administration. These results show that the temporal kinetics of photosensitisation with ALA are very much more favourable than with HpD. The bioavailability of a drug following oral ingestion is usually less than that following intravenous administration due to presystemic drug elimination. First-pass metabolism can occur in the intestinal lumen by the resident flora (Renwick, 1982) , within the wall of the gastrointestinal tract (Caldwell & Marsh, 1982) and in the liver (George & Shand, 1982) . The usefulness of the oral route of administration for ALA will depend on the efficiency of its absorption and the extent of these various forms of first-pass metabolism. Special transport mechanisms exist for amino acids (Van Dyke, 1989 ) and although little is known about the mechanism of ALA absorption from the alimentary tract, it can be expected to undergo similar absorption processes. Following ingestion, ALA needs to pass through intestinal enterocytes before entering the portal and finally systemic circulation. While the extent of ALA metabolism by the normal gut flora is largely unknown, the gastrointestinal mucosal cells have been shown to possess a large capacity of PpIX biosynthesis after intravenous administration Loh et al., 1992) . In addition, the liver has by far the largest capacity for haem synthesis outside the haemopoietic system (Sardesai et al., 1964) . A degree of first pass metabolism of the absorbed ALA can be expected within the mucosal cells to produce porphyrins and haem. In the liver, the extent of first pass metabolism of ALA depends on portal blood flow and the metabolic activity of hepatic enzymes (Genecin et al., 1991) . In the presence of portal hypertension for example, considerable portal systemic shunting can occur (Arroyo et al., 1991) which will affect the extent of hepatic first pass metabolism. In a normal liver, there is maximal enzymatic activity and minimal portal systemic shunting and hepatic first pass metabolism is likely to be considerable. A very high extent of hepatic first pass metabolism of a drug will greatly reduce its systemic bioavailability. In the case of ALA, while any fluorescence build up in the gastrointestinal mucosa may represent local absorption, good systemic bioavailability of ALA following oral ingestion is indicated by fluorescence build up in organs outside the gastrointestinal tract. In this study, we have chosen to evaluate the bladder, an organ in which PDT has considerable clinical potential (Pope et al., 1991) .
In the first part of this study, we have shown that in all three organs investigated, the temporal fluorescence kinetics after oral administration were comparable with that after intravenous injection, indicating rapid and reliable absorption of ALA following ingestion. However, as a result of presystemic metabolism, the absolute tissue concentrations of PpIX produced by 400 mg kg-' of ALA administered enterally were only comparable to those produced by 200 mg kg-' of ALA administered parenterally in all three tissue types. Good systemic bioavailability for photosensitisation after oral administration was demonstrated by the build up of PpIX fluorescence in the bladder. Photosensitisation of the bladder mucosa can come from blood borne ALA or from direct absorption of excreted urinary ALA. Any significant urinary ALA excretion requires a good serum ALA level and would be a further indication of systemic bioavailability although we have not investigated this aspect.
It is also apparent that for a given dose of ALA, the level of PpIX fluorescence build up differs from one epithelial tissue to another, irrespective of the route of administration. Thus, the gastric mucosa shows the highest level of PpIX accumulation followed by colonic and then vesical mucosa. This difference in PpIX biosynthesis capacity between different epithelial tissue is likely to correlate with the differential requirement of these tissues for haem, an important component in the vital respiratory'pigments, and probably reflects their different metabolic rates. Gastric mucosa, consists of actively secretory epithelial cells and can be expected to have a higher metabolic demand than for the bladder mucosa, a non secretory epithelium. We have shown that a rat colon tumour has higher PpIX synthetic capacity in the presence of exogenous ALA as compared with normal colonic mucosa, probably due to a higher level of cell metabolism . It will be interesting to see if adenocarcinomas with varying degrees of differentation and thus secretory function as well as growth rate exhibit similar variation although no data on this is yet available. In the normal organs, the different extent of PpIX accumulation in the main tissue layers gives rise to different degrees of mucosal selectivity. The extent of this differential at the time of light exposure will determine the degree of selectivity of the subsequent tissue necrosis that can be achieved. Although highest levels of mucosal selectivity were achieved 1 h following administration of ALA (Figure 6 ), tissue fluorescence levels only reach their maxima between 2 and 4 h after administration (Figures 3a and b, 4a and b and 5a and b) . Unless a reliable quantity of PpIX can be accumulated by 1 h, light exposure would be better carried out at the time of peak fluorescence to ensure consistent tissue effect. Over this period, mucosal fluorescence was approximately ten times that of muscularis in the stomach, seven times in the colon and five times in the bladder (Figure 6 ). These ratios are higher than the best tumour: normal ratio of conventional photosensitisers such as HpD or phthalocyanine (Agrez et al., 1983; Gomer & Dougherty, 1979; Tralau et al., 1987) . It is worth emphasising that the ratios between neoplastic mucosa and underlying muscle are likely to be even higher in these organs as already demonstrated in the colon . However, a mucosa to muscle ratio of 5 in the bladder is marginally better than that attained in the bladder using intravenous aluminium sulphonated phthalocyanine when a ratio of between 3 and 4 was achieved (Pope et al., 1991) . Pope et al. were able to exploit this relatively small ratio with phthalocyanine photosensitisation at a dose of 0.5 mg kg' to destroy bladder mucosa while not damaging muscle and so preserving bladder function (Pope et al., 1991) . At this dose, the concentration in the mucosa was above the threshold for PDT damage whereas that in the muscle was below the threshold. We would antipicate that similar selective necrosis of vesical mucosa (as required for safe treatment of carcinoma in situ ) would be possible in the bladder using ALA given orally or intravenously.
In the second part of this study, we have demonstrated that an oral dose of 40 mg kg-' of ALA led to only a very small fluorescence level and even in the gastric mucosa, this level was lower than that attained with 20 mg kg' given intravenously (Loh et al., 1992) . It would appear that an oral dose in excess of 40 mg kg' is required to achieve reliable systemic bioavailability of ALA for induction of photosensitisation in normal rat tissue. However, it is important to bear in mind that the degradation (by ferrochelatase) of PpIX synthesised at very low bioavailability of ALA is probably no longer rate limiting, as in the situation found in normal tissue in the absence of exogenously supplied ALA, and consequently PpIX accumulation does not occur. There is evidence to show that ferrochelatase activity in some tumour tissues is reduced (Dailey & Smith, 1984; Schoenfeld et al., 1988; El-Sharabasy et al., 1992) and therefore, accumulation of PpIX in tumour tissue may occur even at such low oral dose. If this can be achieved, truly tumour selective photodynamic effects may yet be possible.
We can estimate peak mucosal levels found in this work to be about 10 pg g'l (Loh et al., in press) which we know (Loh et al., 1992) are more than sufficient to produce full thickness necrosis of normal stomach using 50 J at 630 nm. Fluorescence profiles in both normal and tumour tissue in the three human volunteers confirmed that systemically administered ALA can produce levels of PpIX fluorescence which on the basis these animal studies (Loh et al., 1992) (Berlin et al., 1956 (Loh et al., 1992) . The risk of incomplete tumour photosensitisation may be obviated by using a higher ALA dose but this may be at the expense of loosing tumour selectivity as underlying normal tissue structures such as muscle also become sensitised. Alternatively, continuous ALA administration over a period of time may help to reduce the effect of cell cycle asynchrony of the tumour cells within the same tumour. As long as the rate of PpIX synthesis over that period of time exceeds the rate of PpIX elimination, PpIX accumulation can still be expected to occur. Such an approach has recently been used to selectively induce PpIX sensitisation of liver metastases (van Hillegersberg et al., 1992) . Finally, combination of the direct cellular effect by ALA with an exogenous vascular photosensitiser may be considered. However, unless the exogenous photosensitiser used has similar photochemical characteristics as PpIX, such an approach would be complicated as it would involve excitation at two different wavelengths. Furthermore, the advantageous temporal kinetics of ALA induced photosensitisation will also be overriden by the kinetics of the exogenous photosensitiser used.
In conclusion, ALA administered orally produces similar temporal fluorescence kinetics as that from intravenous administration. Due to first-pass metabolism, a higher oral dose of ALA is required to achieve the same level of photosensitisation as intravenous administration and a dose in excess of 40 mg kg-' is required to produce consistent photosensitisation in normal mucosa in rats. Mucosal selectivity is comparable between the two routes of administration. Oral ALA at a dose of 30 mg kg-' appears to lead to PpIX accumulation in normal human colonic mucosa and adenocarcinoma. ALA is unique as being the only agent for PDT reported thus far which can produce reliable photosensitisation when administered orally. Further evaluation of photosensitisation kinetics and preliminary clinical studies of PDT using orally administered ALA are under way. 
